When we compared immunotherapy response among different risk groups, we noted that in CTLA-4 positive/PD-L renal cell carcinoma patients, the response rate to immunotherapy was significantly higher in the high-risk group than in the low-risk group, while there was no discrepancy in the efficacy of immunotherapy among different risk groups in CTLA-4 negative/PD-L patients. This evidence concerns the gene CTLA4 and hereditary clear cell renal cell carcinoma.